CRISPR-Cas9 Milestones:The First In Vivo Clinical Trial Is Now Underway
In a contributed article published by Pharma’s Almanac, Dr. Lydia Michaut of BioAgilytix discusses CRISPR-Cas9 genome editing technology to understand its promising benefits and the potential challenges of anti-Cas9 immunity as the first human in vivo clinical trial gets underway.
Share This